Meda Acquires North Amercian Rights to Potential Blockbuster from BDSI
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 88 (Table of Contents)
Published: 7 Oct-2007
DOI: 10.3833/pdr.v2007.i88.278 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Meda entered into an exclusive and perpetual license agreement with BioDelivery Sciences International (BDSI) to market BEMA(TM) Fentanyl for the treatment of breakthrough cancer pain in Canada, Mexico and US...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS